Alcon Acquired by Novartis
On December 15, 2010, Novartis (NYSE: NVS) agreed to acquire the remaining shares of Alcon, Inc. (NYSE: ACL) it doesn't currently own for $168 per share.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
View Older Stories View More Recent Stories
-
RxSight Announces Appointments to its Board of Directors
-
RxSight Announces Appointments to its Board of Directors
-
The Galien Foundation Debuts 2021 Prix Galien USA Nominees in "Best Biotechnology Product," "Best Pharmaceutical Agent," "Best Medical Technology" and "Best Digital
-
Ault Global Holdings (DPW) to Acquire up to 40% of Adtech Pharma, Inc.
-
Ault Global Holdings Announces Agreement to Acquire up to 40% of Adtech Pharma, Inc.
-
2020 On-site Forms Industry and Scientific Advisory Board
-
Greg Kunst Appointed CEO of Aurion Biotech
-
Alcon to Showcase Vision Care Innovation, Including Clinical Data for its Forthcoming Reusable Monthly Lens TOTAL30, at BCLA 2021
-
Alcon to Showcase Vision Care Innovation, Including Clinical Data for its Forthcoming Reusable Monthly Lens TOTAL30, at BCLA 2021
-
Opthea (OPT) Named Dr. Julia Haller and Ms. Judith Robertson to Board
-
Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directors
-
Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directors
-
Alcon Reports First Quarter 2021 Results
-
Alcon Reports First Quarter 2021 Results
-
Alcon (ALC) to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
-
Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
-
Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
-
Antares Pharma Appoints Dr. Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer
-
Orasis Pharmaceuticals Appoints Industry Veteran, Paul Smith, as President and Chief Operating Officer to Lead the Next Phase of Growth
-
Ora Appoints David P. Bingaman, DVM, PhD, D. ACVO in Newly Created Chief Development Officer Position
-
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces appointment of Dr Rajkumar Patil as Chief Scientific Officer
-
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces appointment of Dr Rajkumar Patil as Chief Scientific Officer
-
Outset Medical Appoints Global Consumer Brand Builder Andrea Saia to Board of Directors
-
Alcon Inc. (ALC) Capital Markets Day Is Likely a Positive Catalyst - Jefferies
-
UPDATE: BTIG Upgrades Alcon Inc. (ALC) to Buy
-
Alcon Reports Fourth Quarter and Full Year 2020 Results
-
Alcon Reports Fourth Quarter and Full Year 2020 Results
-
908 Devices Appoints Jeff George and Fenel Eloi to its Board of Directors
-
PYC Therapeutics Expands U.S. Executive Leadership Team with the Appointment of Glenn Noronha, PhD, as Chief Development Officer
-
Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the U.S.
-
Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the U.S.
-
Dorian Therapeutics Appoints Jeff George to Board of Directors
-
Publicis Groupe: Full Year 2020 Results
-
Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company’s Executive Team
-
Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company’s Executive Team
-
The BlocPartners Honored with the Selection of Two Jurors for the Clio Health Awards
-
Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.
-
Alcon Launches PRECISION1 for Astigmatism Contact Lenses in the U.S.
-
Alcon Launches PRECISION1 for Astigmatism Contact Lenses in the U.S.
-
Beyeonics Surgical appoints Dr. Sharon Bakalash MD, PhD as Chief Medical officer
-
ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications
-
CDK Global (CDK) Announces Eric Guerin as CFO
-
CDK Global Names Eric Guerin Chief Financial Officer
-
Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers
-
Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers
-
4D Molecular Therapeutics Strengthens Leadership Team with Key Appointments in Clinical Research and Development
-
Matinas BioPharma Appoints Hui Liu, Ph.D., M.B.A. as Chief Technology Officer
-
Matinas BioPharma Appoints Hui Liu, Ph.D., M.B.A. as Chief Technology Officer
-
Alcon Reports Third Quarter 2020 Results
-
Alcon Reports Third Quarter 2020 Results
